Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
This is a Phase 1/2, open-label, dose-escalation, dose-expansion study for the treatment of patients with advanced cancers. Eligible patients with DLBCL or other advanced lymphomas will be enrolled into the dose-expansion cohort.
Advanced Cancers|DLBCL|Lymphoma
DRUG: IONIS-STAT3Rx
Safety of IONIS-STAT3Rx in patients with Advanced Cancers, Approximately 28 days after last dose of IONIS -STAT3Rx|Maximum-tolerated dose (MTD) of IONIS-STAT3Rx in patients with Advanced Cancers., Highest dose level at which no more than 1 out of 6 patients develops a DLT, Approximately 28 Days
Clinical activity of IONIS-STAT3Rx, Measured by RECIST in the study population who have measurable disease or relevant disease specific response criteria, Approximately 28 Days after last dose of IONIS-STAT3Rx|Pharmacokinetics-Cmax, Maximum observed drug concentration (Cmax), Approximately 28 days after last dose of IONIS-STAT3Rx|STAT3 and other biomarkers, The effect of treatment with IONIS-STAT3Rx on phospho-STAT3 and other biomarkers, Approximately 28 days after last dose of IONIS-STAT3Rx|Pharmacokinetics - Tmax, Time taken to reach Cmax, Approximately 28 days after last dose of IONIS-STAT3Rx
This is a Phase 1/2, open-label, dose-escalation, dose-expansion study for the treatment of patients with advanced cancers. Eligible patients with DLBCL or other advanced lymphomas will be enrolled into the dose-expansion cohort.